Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vivos Therapeutics (VVOS) Change in Cash (2020 - 2025)

Vivos Therapeutics' Change in Cash history spans 6 years, with the latest figure at -$1.1 million for Q4 2025.

  • Quarterly results put Change in Cash at -$1.1 million for Q4 2025, down 1974.51% from a year ago — trailing twelve months through Dec 2025 was -$4.2 million (down 191.64% YoY), and the annual figure for FY2025 was -$4.2 million, down 191.64%.
  • Change in Cash for Q4 2025 was -$1.1 million at Vivos Therapeutics, up from -$1.3 million in the prior quarter.
  • In the past five years, Change in Cash ranged from a high of $20.1 million in Q2 2021 to a low of -$6.2 million in Q1 2022.
  • The 5-year median for Change in Cash is -$2.1 million (2023), against an average of -$808850.0.
  • The sharpest move saw Change in Cash soared 6463.13% in 2021, then tumbled 1974.51% in 2025.
  • Year by year, Change in Cash stood at -$4.5 million in 2021, then grew by 28.95% to -$3.2 million in 2022, then surged by 120.47% to $655000.0 in 2023, then tumbled by 107.79% to -$51000.0 in 2024, then tumbled by 1974.51% to -$1.1 million in 2025.
  • According to Business Quant data, Change in Cash over the past three periods came in at -$1.1 million, -$1.3 million, and $2.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.